Case: Patents/Anticipation & Obviousness (Fed. Cir.)

The Federal Circuit affirmed in part, vacated in part, and remanded the decision of the Patent Trial and Appeal Board holding claims of Bayer Pharma Aktiengesellschaft’s patent directed to methods for reducing the risk of cardiovascular events in patients with coronary artery disease and/or peripheral artery disease by administering rivaroxaban and aspirin unpatentable as anticipated by and obvious over prior art, in an inter partes review by Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., and Invagen Pharmaceuticals Inc. The court affirmed the board’s judgment holding four claims unpatentable, and vacated and remanded the judgment of unpatentability with respect to four ...